ID

33727

Beschreibung

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification; ODM derived from: https://clinicaltrials.gov/show/NCT01664247

Link

https://clinicaltrials.gov/show/NCT01664247

Stichworte

Versionen (1)
  1. 21.12.18 21.12.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

21. Dezember 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Diabetes NCT01664247

Englisch

Eligibility Diabetes NCT01664247

1 Formulare  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01664247
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes
Beschreibung

Diabetes Mellitus, Non-Insulin-Dependent

Datentyp

boolean

Alias
UMLS CUI [1]
C0011860
insulin naïve
Beschreibung

Insulin Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0021641
UMLS CUI [1,2]
C0332197
ongoing treatment with metformin or metformin in combination with either sulphonylurea (su), glinides, dipeptidyl peptidase-iv (dpp-iv) inhibitors or exenatide (only twice daily (bid))
Beschreibung

Metformin | Combined Modality Therapy | Sulfonylurea | Glinide | Dipeptidyl-Peptidase IV Inhibitors | Exenatide Twice a day

Datentyp

boolean

Alias
UMLS CUI [1]
C0025598
UMLS CUI [2]
C0009429
UMLS CUI [3]
C0038766
UMLS CUI [4]
C2266929
UMLS CUI [5]
C1827106
UMLS CUI [6,1]
C0167117
UMLS CUI [6,2]
C0585361
glycosylated haemoglobin (hba1c) (by central laboratory analysis): a. 7.5-10.0 % (both inclusive) for subjects on metformin monotherapy, b. 7.0-9.0 % (both inclusive) for subjects on metformin in combination with either su, glinides, dpp-iv inhibitors or exenatide (only bid)
Beschreibung

Hemoglobin A1c measurement | Metformin | Combined Modality Therapy | Sulfonylurea | Glinide | DPP-IV Inhibitors | Exenatide Twice a day

Datentyp

boolean

Alias
UMLS CUI [1]
C0474680
UMLS CUI [2]
C0025598
UMLS CUI [3]
C0009429
UMLS CUI [4]
C0038766
UMLS CUI [5]
C2266929
UMLS CUI [6]
C1827106
UMLS CUI [7,1]
C0167117
UMLS CUI [7,2]
C0585361
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment with glucose-lowering agent(s) other than stated in the inclusion criteria within 12 weeks
Beschreibung

Hypoglycemic Agents | Exception Inclusion criteria

Datentyp

boolean

Alias
UMLS CUI [1]
C0020616
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1512693
calcitonin equal to or above 50 pg/ml
Beschreibung

Calcitonin Dose

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0006668
UMLS CUI [1,2]
C0178602
stroke; heart failure new york heart association (nyha) class iii or iv; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within 24 weeks
Beschreibung

Cerebrovascular accident | Heart failure New York Heart Association Classification | Myocardial Infarction | Angina, Unstable | Coronary Artery Bypass Surgery | Angioplasty

Datentyp

boolean

Alias
UMLS CUI [1]
C0038454
UMLS CUI [2,1]
C0018801
UMLS CUI [2,2]
C1275491
UMLS CUI [3]
C0027051
UMLS CUI [4]
C0002965
UMLS CUI [5]
C0010055
UMLS CUI [6]
C0162577
current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell carcinoma)
Beschreibung

Malignant Neoplasms | Exception Basal cell carcinoma | Exception Squamous cell carcinoma

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007137
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Diabetes NCT01664247

1 Formulare
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01664247
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Insulin Absent
Item
insulin naïve
boolean
C0021641 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Metformin | Combined Modality Therapy | Sulfonylurea | Glinide | Dipeptidyl-Peptidase IV Inhibitors | Exenatide Twice a day
Item
ongoing treatment with metformin or metformin in combination with either sulphonylurea (su), glinides, dipeptidyl peptidase-iv (dpp-iv) inhibitors or exenatide (only twice daily (bid))
boolean
C0025598 (UMLS CUI [1])
C0009429 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
C2266929 (UMLS CUI [4])
C1827106 (UMLS CUI [5])
C0167117 (UMLS CUI [6,1])
C0585361 (UMLS CUI [6,2])
Hemoglobin A1c measurement | Metformin | Combined Modality Therapy | Sulfonylurea | Glinide | DPP-IV Inhibitors | Exenatide Twice a day
Item
glycosylated haemoglobin (hba1c) (by central laboratory analysis): a. 7.5-10.0 % (both inclusive) for subjects on metformin monotherapy, b. 7.0-9.0 % (both inclusive) for subjects on metformin in combination with either su, glinides, dpp-iv inhibitors or exenatide (only bid)
boolean
C0474680 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
C0038766 (UMLS CUI [4])
C2266929 (UMLS CUI [5])
C1827106 (UMLS CUI [6])
C0167117 (UMLS CUI [7,1])
C0585361 (UMLS CUI [7,2])
Item Group
C0680251 (UMLS CUI)
Hypoglycemic Agents | Exception Inclusion criteria
Item
treatment with glucose-lowering agent(s) other than stated in the inclusion criteria within 12 weeks
boolean
C0020616 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1512693 (UMLS CUI [2,2])
Calcitonin Dose
Item
calcitonin equal to or above 50 pg/ml
boolean
C0006668 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
Cerebrovascular accident | Heart failure New York Heart Association Classification | Myocardial Infarction | Angina, Unstable | Coronary Artery Bypass Surgery | Angioplasty
Item
stroke; heart failure new york heart association (nyha) class iii or iv; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within 24 weeks
boolean
C0038454 (UMLS CUI [1])
C0018801 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
C0027051 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0010055 (UMLS CUI [5])
C0162577 (UMLS CUI [6])
Malignant Neoplasms | Exception Basal cell carcinoma | Exception Squamous cell carcinoma
Item
current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell carcinoma)
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007137 (UMLS CUI [3,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video